ABSTRACT
We present a case of locally advanced rectal cancer with initial optimal local control after neoadjuvant concurrent chemoradiotherapy followed by surgery; early liver recurrence then occurred and was treated again with curative intent with neoadjuvant combination chemotherapy followed by liver surgery. We reflect on this difficult problem and discuss relevant topics to this case report.
Subject(s)
Liver Neoplasms/secondary , Liver Neoplasms/surgery , Rectal Neoplasms/surgery , Antimetabolites, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/therapeutic use , Combined Modality Therapy , Fluorouracil/administration & dosage , Fluorouracil/therapeutic use , Humans , Neoadjuvant Therapy , Neoplasm Staging , Rectal Neoplasms/diagnosis , Rectal Neoplasms/drug therapy , Rectal Neoplasms/pathology , Rectal Neoplasms/radiotherapy , Rectum/pathologyABSTRACT
No disponible
Subject(s)
Humans , Liver Neoplasms/surgery , Colorectal Neoplasms/surgery , Chemotherapy, Adjuvant/methods , Neoplasm MetastasisABSTRACT
The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease. Trastuzumab, as a second line treatment, has shown a 15% objective response rate in patients with metastatic breast cancer. We present the case of a patient with two breast tumours, the second of more aggressive characteristics, with negative hormone receptors and c-erb-B2 +++, and with few therapeutic options due to her hepatic insufficiency secondary to metastatic disease; she was administered herceptin as monotherapy, and she had a complete clinical response. Trastuzumab has revolutionised the management of patients with metastatic breast cancer and Her-2- neu overexpression. Its combination with chemotherapy agents achieves a synergic activity.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/secondary , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Aged , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/administration & dosage , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Breast/pathology , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/radiotherapy , Carcinoma, Ductal, Breast/surgery , Cisplatin/therapeutic use , Combined Modality Therapy , Disease-Free Survival , Female , Fluorouracil/therapeutic use , Follow-Up Studies , Humans , Karnofsky Performance Status , Liver Neoplasms/diagnostic imaging , Lymphatic Metastasis , Mastectomy, Modified Radical , Methotrexate/therapeutic use , Radiotherapy Dosage , Receptor, ErbB-2 , Tamoxifen/administration & dosage , Tamoxifen/therapeutic use , Time Factors , Tomography, X-Ray Computed , Trastuzumab , Treatment OutcomeABSTRACT
Small cell lung cancer is the most common cause of paraneoplastic Cushing's syndrome. The definitive treatment consists in surgical removal of the tumour, which is not possible in most of these cases (they are often diagnosed at advanced stages), and therefore it is frequently necessary adding the drug ketoconazol. We hereby present the case of a patient diagnosed with a metastatic carcinoma of unknown origin associated with two paraneoplastic syndromes: a Cushing's syndrome and a sensitive-motor axonal neuropathy, a very uncommon association.
Subject(s)
ACTH Syndrome, Ectopic/etiology , Adenocarcinoma/diagnosis , Neoplasms, Unknown Primary/diagnosis , Paraneoplastic Polyneuropathy/etiology , Humans , Male , Middle AgedABSTRACT
No disponible
Small cell lung cancer is the most common cause ofparaneoplastic Cushings syndrome. The definitivetreatment consists in surgical removal of the tumour,which is not possible in most of these cases(they are often diagnosed at advanced stages), andtherefore it is frequently necessary adding the drugketoconazol.We hereby present the case of a patient diagnosedwith a metastatic carcinoma of unknown origin associatedwith two paraneoplastic syndromes: aCushings syndrome and a sensitive-motor axonalneuropathy, a very uncommon association
